A Phase 1/2 interventional study of RO7239361 and Placebo in Muscular Dystrophy (DMD), sponsored by Hoffmann-La Roche. Terminated at 12 sites in 2 countries. Open to male participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Muscular Dystrophies with a site in United States — 32 open to participants now, 43 under way, 2 of them phase 3. Muscular Dystrophies · United States.
Among the 127 studies in Muscular Dystrophies with a site in United States, this one is the 38th largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2015, is one of 9 in phase 1/2, and was the 53rd registered.
224 studies on the registry are indexed under Muscular Dystrophies; 48 are open to participants now.
Browse Muscular Dystrophies studies →32 of the 127 studies in Muscular Dystrophies with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Virginia Commonwealth University · Sites in United States
Ages 18–70
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 5–25
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Muscular Dystrophies studies recruiting now, 14 (37%) set no upper age limit and 15 (39%) stop at 75 or younger; 24 take children under 18; 7 take healthy volunteers.
This study: 5 Years to 10 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 16 · Phase 4 2
First in 1978; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is above the median of 30 across 140 interventional studies indexed under Muscular Dystrophies.
Median enrollment 41 across the 80 interventional studies, 109 across the 44 observational. Of the 76 that completed or were terminated, 28 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 127 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Muscular Dystrophies — fewer than ten, so there is no comparison to draw.
13 of the studies in Muscular Dystrophies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT05854433Wake Forest University Health SciencesBrain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2 | 2027-06 |
| NCT07502989Beth Israel Deaconess Medical CenterMuscle Health Measurements Using Electrical Impedance Myography | 2027-06-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 127 studies in Muscular Dystrophies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RO7239361 subcutaneous injections on specified days
Drug: RO7239361
Placebo subcutaneous injections on specified days
Drug: Placebo
Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Also known as: Anti-Myostatin Adnectin, taldefgrobep alfa
Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Safety Summary for the 24 Week Double-Blind Phase
Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline to Week 24
Safety Summary up to Week 72
Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 72. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline to Week 72
Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.
PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361. No participants received the Panel 2 20mg dose.
Time frame: Day 1: predose, 3, 6, 72 and 96 hours (h) postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW Dose.
PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.
PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW. Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 6. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW Dose.
PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.
PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 8. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW Dose.
PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
RO7239361 Trough Concentrations
Trough concentrations of RO7239361 at different dose levels. Panel 1 = 4mg, Panel 2 = 12.5mg and 20mg, Panel 3 = 35mg, Expansion Panels = 35mg and 50mg. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Double-Blind Phase
A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 8 through Week 24, baseline and on-study information represented in table.
Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment up to Week 72
A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants is not included. Placebo participants in each arm moved on to RO7239361 upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 8 through Week 72, baseline and on-study information represented in table.
Serum Concentration of Free Myostatin in the Double-Blind Phase
Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 24
Percent Inhibition of Free Myostatin in the Double-Blind Phase
Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 24
Serum Concentration of Drug-Myostatin Complex in the Double-Blind Phase
Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 24
Fold Change From Baseline in Contractile Versus Non-contractile Content for Muscles in the Right Thigh in the Double-Blind Phase
Ratio of contractile vs non-contractile content is contractile content / non-contractile content. Fold change from baseline of the ratio is defined as the ratio of fold change from baseline of contractile content vs fold change from baseline of non-contractile content. Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 24
Change From Baseline in Thigh Muscle Maximal Cross Sectional Area (CSAmax) in the Double-Blind Phase
Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 24
Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Whole Study
A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Day 8 through Week 228, baseline and on-study information represented in table.
Serum Concentration of Free Myostatin, Whole Study
Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 252
Percent Inhibition of Free Myostatin, Whole Study
Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 252
Serum Concentration of Drug-Myostatin Complex, Whole Study
Participants in the Placebo arm received placebo during the double-blind (DB) period (up to Week 24) and received RO7239361 during the open label (OL) phase. PFS in table row title indicates when study drug was changed from vial to prefilled syringe (PFS). Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
Time frame: Baseline through Week 252
Doses for this study are based upon achieving a moderate to high degree of suppression in serum free myostatin at steady-state trough across 3 dose levels. A body weight-tiered, fixed-dose strategy targeting moderate (\>50%), high (\>85%) and near complete (\>95%) suppression of serum free myostatin was used to select the three doses for the study.
| Milestone | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|---|
| Started | 11 | 7 | 6 | 19 |
| Completed | 11 | 7 | 6 | 19 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|---|
| Started | 0 | 9 | 8 | 26 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 9 | 8 | 26 |
| Withdrew: Other | 0 | 0 | 1 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
| Withdrew: Subject request to discontinue treatment | 0 | 0 | 2 | 3 |
| Withdrew: Administrative reason by sponsor | 0 | 7 | 2 | 17 |
| Withdrew: Missing | 0 | 2 | 2 | 2 |
Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| percentage of participants | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion RO7239361 |
|---|---|---|---|---|
| Death | 0 | 0 | 0 | 0 |
| Adverse Events (AEs) | 81.8 | 71.4 | 100.0 | 94.7 |
| AEs leading to study withdrawal | 0 | 0 | 0 | 0 |
| Serious Adverse Events (SAE) | 9.1 | 0 | 0 | 5.3 |
| Very Severe AEs | 0 | 0 | 0 | 0 |
| Severe AEs | 0 | 0 | 0 | 0 |
| Related AEs | 27.3 | 14.3 | 50.0 | 36.8 |
Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 72. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| percentage of participants | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Death | 0 | 0 | 0 |
| Adverse Events (AEs) | 100.0 | 100.0 | 96.2 |
| AEs leading to study withdrawal | 0 | 0 | 0 |
| Serious Adverse Events (SAE) | 0 | 25.0 | 7.7 |
| Very Severe AEs | 0 | 0 | 0 |
| Severe AEs | 0 | 25.0 | 3.8 |
| Related AEs | 77.8 | 62.5 | 50.0 |
PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361. No participants received the Panel 2 20mg dose.
| ng/ml | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses. | 3217 ± 15.8 | 8490 ± 21.5 | 24242 ± 26.3 |
PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| ng/mL | Panel 3 and Expansion Panel RO7239361 |
|---|---|
| Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW Dose. | 23297 ± NA |
PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW. Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 6. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| hour | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses. | 28 (12 to 48) | 24 (11 to 47) | 30 (11 to 65) |
PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| hour | Panel 3 and Expansion Panel RO7239361 |
|---|---|
| Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW Dose. | 44 (NA to NA) |
PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 8. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| ng•day/mL | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses. | 18676 ± 23 | 51461 ± 18 | 150609 ± 24 |
PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| ng•day/mL | Panel 3 and Expansion Panel RO7239361 |
|---|---|
| Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW Dose. | 151000 ± NA |
Trough concentrations of RO7239361 at different dose levels. Panel 1 = 4mg, Panel 2 = 12.5mg and 20mg, Panel 3 = 35mg, Expansion Panels = 35mg and 50mg. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| ng/mL | Panel 1 RO7239361 | Panel 2 RO7239361 12.5mg | Panel 2 RO7239361 20mg | Panel 3 RO7239361 35mg | Expansion Panel RO7239361 35mg | Expansion Panel RO7239361 50mg |
|---|---|---|---|---|---|---|
| Day 1 | 825.343 ± 23 | 2115.951 ± 20 | — | 6559.364 ± 26 | 6017.978 ± 23 | 5020.000 ± NA |
| Day 15 | 1258.746 ± 35 | 3697.590 ± 20 | — | 9957.352 ± 34 | 9944.183 ± 24 | 9980.000 ± NA |
| Day 22 | 1640.052 ± 15 | 4220.280 ± 32 | — | 12383.747 ± 30 | 13215.188 ± 24 | NA ± NA |
| Day 29 | 2015.695 ± 32 | 5107.668 ± 25 | — | 14110.005 ± 34 | 15094.455 ± 19 | NA ± NA |
| Day 84 | 2179.385 ± 26 | 6484.502 ± 19 | — | 19332.421 ± 20 | 18789.382 ± 18 | 27800.000 ± NA |
| Day 168 | 2438.595 ± 16 | 6100.315 ± 25 | 6340.000 ± NA | 19923.182 ± 41 | 12580.299 ± 41 | 26200.000 ± NA |
A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| percentage of participants | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|---|
| Baseline (BL): ADA Positive | 0 | 0 | 0 | 0 |
| BL: ADA Negative | 0 | 71.4 | 100.0 | 89.5 |
| BL: Missing | 100.0 | 28.6 | 0 | 10.5 |
| On-treatment: ADA Positive | 0 | 0 | 0 | 0 |
| On-treatment: Persistent Positive | 0 | 0 | 0 | 0 |
| On-treatment: Only last sample Positive | 0 | 0 | 0 | 0 |
| On-treatment: Other Positive | 0 | 0 | 0 | 0 |
| On-treatment: ADA Negative | 0 | 100.0 | 100.0 | 100.0 |
| On-treatment: ADA Negative, BL Positive, No Boost | 0 | 0 | 0 | 0 |
| On-treatment: Missing | 100.0 | 0 | 0 | 0 |
A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants is not included. Placebo participants in each arm moved on to RO7239361 upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| percentage of participants | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Baseline (BL): ADA Positive | 0 | 0 | 0 |
| BL: ADA Negative | 77.8 | 87.5 | 88.5 |
| BL: Missing | 22.2 | 12.5 | 11.5 |
| On-treatment: ADA Positive | 0 | 0 | 3.8 |
| On-treatment: Persistent Positive | 0 | 0 | 0 |
| On-treatment: Only last sample Positive | 0 | 0 | 3.8 |
| On-treatment: Other Positive | 0 | 0 | 0 |
| On-treatment: ADA Negative | 100.0 | 100.0 | 96.2 |
| On-treatment: ADA Negative, BL Positive, No Boost | 0 | 0 | 0 |
| On-treatment: Missing | 0 | 0 | 0 |
Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| pg/mL | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|---|
| Baseline | 1405.1 ± 809.57 | 815.3 ± 155.14 | 1391.3 ± 1084.97 | 1121.8 ± 526.45 |
| Day 4 | 1356.6 ± 641.27 | 421.4 ± 70.60 | 321.3 ± 165.91 | 58.3 ± 33.20 |
| Day 5 | 1438.2 ± 809.18 | 446.6 ± 108.81 | 357.8 ± 166.27 | 66.1 ± 39.07 |
| Day 8 | 1014.2 ± 549.26 | 522.7 ± 131.51 | 479.2 ± 319.13 | 206.8 ± 419.21 |
| Day 15 | 1266.9 ± 611.27 | 478.4 ± 111.44 | 280.8 ± 148.53 | 54.8 ± 61.85 |
| Day 22 | 1317.1 ± 728.48 | 382.4 ± 82.58 | 284.8 ± 324.16 | 35.3 ± 51.45 |
| Day 29 | 1214.0 ± 676.80 | 372.3 ± 79.97 | 179.0 ± 137.39 | 24.8 ± 27.24 |
| Day 33 | 1141.4 ± 606.99 | 291.1 ± 77.55 | 115.7 ± 84.49 | 24.3 ± 30.64 |
| Week 12 | 1366.5 ± 631.28 | 307.8 ± 97.84 | 110.8 ± 49.80 | 16.2 ± 11.60 |
| Week 24 | 1194.0 ± 599.59 | 297.1 ± 74.62 | 160.8 ± 122.75 | 23.4 ± 25.34 |
Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| percentage inhibition | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|---|
| Day 4 | 0.595 ± 23.6952 | 49.689 ± 11.7394 | 73.533 ± 9.8637 | 95.334 ± 2.4477 |
| Day 5 | 3.114 ± 20.3395 | 46.506 ± 9.0917 | 69.700 ± 10.3411 | 94.545 ± 2.7608 |
| Day 8 | 23.917 ± 31.1378 | 38.411 ± 7.0320 | 62.524 ± 9.7074 | 84.797 ± 22.1958 |
| Day 15 | 5.744 ± 18.6190 | 40.763 ± 10.0071 | 77.090 ± 6.2939 | 96.488 ± 1.9665 |
| Day 22 | 5.561 ± 11.7425 | 51.836 ± 9.3488 | 81.693 ± 5.7392 | 97.927 ± 1.1259 |
| Day 29 | 12.599 ± 16.1591 | 52.926 ± 6.6001 | 86.894 ± 2.9590 | 98.202 ± 1.4590 |
| Day 33 | 15.662 ± 17.3640 | 61.796 ± 4.5760 | 91.557 ± 2.6444 | 97.042 ± 5.4443 |
| Week 12 | 5.289 ± 15.5082 | 60.254 ± 9.4283 | 92.454 ± 1.7243 | 98.415 ± 1.2882 |
| Week 24 | 9.910 ± 17.8109 | 63.790 ± 5.7031 | 88.392 ± 5.1669 | 97.921 ± 2.2143 |
Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| ng/mL | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|---|
| Day 4 | 1.178 ± 1.8833 | 5.070 ± 0.9456 | 12.606 ± 5.7623 | 14.696 ± 5.7926 |
| Day 5 | 2.119 ± 2.9826 | 5.845 ± 2.5725 | 14.856 ± 7.6131 | 17.308 ± 7.5955 |
| Day 8 | 4.924 ± 12.9975 | 7.041 ± 2.3470 | 19.906 ± 9.8664 | 21.609 ± 11.0880 |
| Day 15 | 0.613 ± 0.2102 | 14.067 ± 7.1096 | 29.229 ± 10.4929 | 45.289 ± 18.7600 |
| Day 22 | 1.326 ± 1.3410 | 11.985 ± 4.8243 | 36.811 ± 26.8560 | 52.841 ± 21.5542 |
| Day 29 | 1.593 ± 3.1007 | 15.735 ± 4.2010 | 43.236 ± 34.0300 | 67.255 ± 27.9376 |
| Day 33 | 1.157 ± 1.0036 | 18.542 ± 3.9874 | 46.279 ± 24.1457 | 77.142 ± 32.4153 |
| Week 12 | 7.082 ± 15.2289 | 28.556 ± 22.7890 | 79.555 ± 17.2126 | 88.402 ± 29.8080 |
| Week 24 | 3.589 ± 7.8108 | 25.997 ± 6.4384 | 83.262 ± 64.2281 | 101.406 ± 45.4197 |
Ratio of contractile vs non-contractile content is contractile content / non-contractile content. Fold change from baseline of the ratio is defined as the ratio of fold change from baseline of contractile content vs fold change from baseline of non-contractile content. Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| Fold Change | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 RO7239361 | Expansion Panel RO7239361 |
|---|---|---|---|---|---|
| W12: ADDUCTOR LONGUS | 1.04 ± 0.291 | 0.95 ± 0.088 | 1.16 ± 0.330 | 2.27 ± 1.122 | 2.36 ± 0.875 |
| W12: ADDUCTOR MAGNUS | 0.69 ± 0.104 | 0.88 ± 0.283 | 1.12 ± 0.281 | 0.93 ± 0.255 | 1.04 ± 0.101 |
| W12: BICEPS FEMORIS LONG | 0.78 ± 0.221 | 0.94 ± 0.304 | 1.57 ± 0.556 | 1.10 ± 0.280 | 1.26 ± 0.237 |
| W12: BICEPS FEMORIS SHORT | 0.92 ± 0.269 | 2.77 ± 1.144 | 2.03 ± 1.564 | 0.79 ± 0.162 | 1.31 ± 0.301 |
| W12: GRACILIS | 1.13 ± 0.318 | 7.57 ± 5.372 | 0.98 ± 0.176 | 3.41 ± 2.474 | 5.42 ± 3.871 |
| W12:RECTUS FEMORIS | 0.74 ± 0.185 | 0.55 ± 0.134 | 4.49 ± 2.729 | 0.99 ± 0.345 | 2.02 ± 0.764 |
| W12: SARTORIUS | 1.78 ± 0.771 | 0.69 ± 0.307 | 1.04 ± 0.443 | 0.90 ± 0.396 | 2.00 ± 0.683 |
| W12: SEMIMEMBRANOSUS | 0.82 ± 0.230 | 0.82 ± 0.284 | 1.47 ± 0.777 | 0.86 ± 0.276 | 1.31 ± 0.194 |
| W12: SEMITENDINOSUS | 0.78 ± 0.262 | 2.95 ± 1.016 | 1.31 ± 0.260 | 1.42 ± 0.317 | 1.17 ± 0.160 |
| W12: VASTUS INTERMEDIUS | 2.59 ± 1.749 | 1.11 ± 0.292 | 0.62 ± 0.258 | 0.86 ± 0.157 | 1.64 ± 0.377 |
| W12: VASTUS LATERALIS | 0.66 ± 0.160 | 0.89 ± 0.272 | 1.10 ± 0.333 | 1.78 ± 0.455 | 1.70 ± 0.334 |
| W12: VASTUS MEDIALIS | 1.08 ± 0.269 | 1.26 ± 0.112 | 2.97 ± 1.981 | 0.85 ± 0.280 | 5.96 ± 3.376 |
| W24: ADDUCTOR LONGUS | 0.81 ± 0.290 | 1.14 ± 0.269 | 1.11 ± 0.471 | 1.36 ± 0.718 | 2.41 ± 0.813 |
| W24: ADDUCTOR MAGNUS | 0.66 ± 0.112 | 0.94 ± 0.296 | 0.59 ± 0.144 | 1.61 ± 0.697 | 1.14 ± 0.146 |
| W24: BICEPS FEMORIS LONG | 1.07 ± 0.511 | 1.13 ± 0.315 | 1.00 ± 0.349 | 1.29 ± 0.238 | 2.10 ± 1.044 |
| W24: BICEPS FEMORIS SHORT | 0.91 ± 0.195 | 2.24 ± 1.027 | 2.15 ± 1.003 | 1.24 ± 0.411 | 2.02 ± 0.416 |
| W24: GRACILIS | 1.43 ± 0.686 | 3.03 ± 2.564 | 1.37 ± 0.465 | 1.45 ± 0.748 | 5.17 ± 3.540 |
| W24:RECTUS FEMORIS | 0.94 ± 0.256 | 0.84 ± 0.220 | 7.43 ± 6.216 | 0.80 ± 0.262 | 3.01 ± 1.612 |
| W24: SARTORIUS | 1.90 ± 0.872 | 0.73 ± 0.207 | 0.78 ± 0.375 | 3.24 ± 1.850 | 2.45 ± 0.842 |
| W24: SEMIMEMBRANOSUS | 0.66 ± 0.126 | 0.90 ± 0.361 | 0.72 ± 0.157 | 0.94 ± 0.250 | 1.39 ± 0.256 |
| W24: SEMITENDINOSUS | 0.56 ± 0.119 | 1.59 ± 0.520 | 1.43 ± 0.524 | 1.04 ± 0.254 | 1.22 ± 0.221 |
| W24: VASTUS INTERMEDIUS | 0.95 ± 0.412 | 1.47 ± 0.446 | 0.63 ± 0.355 | 0.96 ± 0.095 | 1.47 ± 0.318 |
| W24: VASTUS LATERALIS | 0.78 ± 0.159 | 1.88 ± 0.905 | 1.45 ± 0.596 | 1.43 ± 0.256 | 2.03 ± 0.484 |
| W24: VASTUS MEDIALIS | 2.14 ± 0.889 | 5.16 ± 3.580 | 6.01 ± 5.478 | 1.29 ± 0.474 | 3.50 ± 1.390 |
Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| Percentage Change | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3RO7239361 | Expansion Panel RO7239361 |
|---|---|---|---|---|---|
| W12: ADDUCTOR LONGUS | 7.29 ± 16.559 | 8.31 ± 11.767 | 5.85 ± 11.074 | 14.61 ± 9.755 | 29.98 ± 8.530 |
| W12: ADDUCTOR MAGNUS | 31.01 ± 24.708 | 24.12 ± 11.804 | -3.73 ± 29.037 | 53.20 ± 25.328 | 4.01 ± 54.787 |
| W12: BICEPS FEMORIS LONG | 34.24 ± 18.328 | 33.43 ± 35.009 | 16.72 ± 17.806 | 19.22 ± 9.802 | 23.93 ± 11.289 |
| W12: BICEPS FEMORIS SHORT | 14.10 ± 7.724 | 7.45 ± 11.592 | 2.69 ± 13.733 | 18.68 ± 7.479 | 9.84 ± 3.882 |
| W12: GRACILIS | 20.14 ± 15.489 | 43.00 ± 28.539 | 15.28 ± 8.693 | 27.02 ± 5.686 | 23.22 ± 5.440 |
| W12:RECTUS FEMORIS | -7.86 ± 14.391 | 10.33 ± 11.927 | -3.56 ± 14.175 | 34.91 ± 6.037 | 16.01 ± 9.888 |
| W12: SARTORIUS | 11.26 ± 6.584 | 6.59 ± 11.952 | -0.85 ± 6.383 | 10.81 ± 11.017 | 18.20 ± 5.519 |
| W12: SEMIMEMBRANOSUS | 39.11 ± 15.041 | 32.57 ± 19.133 | 16.56 ± 19.998 | 46.70 ± 16.480 | 31.01 ± 10.564 |
| W12: SEMITENDINOSUS | 25.03 ± 9.409 | -1.24 ± 10.973 | 33.00 ± 26.730 | 36.69 ± 14.802 | 40.10 ± 10.180 |
| W12: VASTUS INTERMEDIUS | 10.47 ± 12.160 | 23.35 ± 12.704 | -52.03 ± 71.421 | -0.81 ± 19.353 | 10.44 ± 7.344 |
| W12: VASTUS LATERALIS | 31.47 ± 39.343 | 38.32 ± 19.570 | 14.08 ± 27.902 | 57.86 ± 34.026 | 22.73 ± 15.138 |
| W12: VASTUS MEDIALIS | -17.89 ± 19.358 | 15.65 ± 8.463 | -11.60 ± 15.849 | 21.14 ± 9.746 | 17.89 ± 6.788 |
| W24: ADDUCTOR LONGUS | 11.69 ± 15.626 | 23.41 ± 13.199 | 12.81 ± 16.393 | 17.15 ± 15.484 | 44.12 ± 13.323 |
| W24: ADDUCTOR MAGNUS | 34.17 ± 24.918 | 21.90 ± 12.345 | -6.71 ± 37.311 | 45.05 ± 27.520 | 4.41 ± 52.393 |
| W24: BICEPS FEMORIS LONG | 39.21 ± 19.760 | 42.84 ± 22.086 | -5.32 ± 29.140 | 33.70 ± 12.073 | 31.33 ± 13.370 |
| W24: BICEPS FEMORIS SHORT | 20.09 ± 9.818 | 11.83 ± 13.013 | -0.44 ± 16.183 | 30.01 ± 13.494 | 18.60 ± 5.394 |
| W24: GRACILIS | 8.14 ± 7.148 | 18.72 ± 16.757 | 11.21 ± 5.461 | 48.95 ± 17.064 | 40.15 ± 8.382 |
| W24:RECTUS FEMORIS | 8.97 ± 10.214 | 7.68 ± 13.082 | -10.01 ± 16.121 | 55.65 ± 27.535 | 38.40 ± 14.293 |
| W24: SARTORIUS | 10.75 ± 7.136 | 0.81 ± 8.143 | -14.18 ± 9.481 | 16.63 ± 4.476 | 25.51 ± 6.404 |
| W24: SEMIMEMBRANOSUS | 45.83 ± 14.896 | 30.01 ± 18.631 | -11.48 ± 24.468 | 61.03 ± 25.524 | 49.49 ± 12.011 |
| W24: SEMITENDINOSUS | 32.00 ± 16.102 | 36.17 ± 23.285 | 24.16 ± 23.403 | 73.68 ± 17.594 | 62.55 ± 11.073 |
| W24: VASTUS INTERMEDIUS | 14.86 ± 15.072 | 43.01 ± 11.506 | -68.05 ± 86.362 | 41.63 ± 34.926 | 22.55 ± 8.284 |
| W24: VASTUS LATERALIS | 12.95 ± 35.465 | 47.79 ± 26.178 | 32.64 ± 30.136 | 45.41 ± 43.774 | 46.87 ± 20.919 |
| W24: VASTUS MEDIALIS | -9.09 ± 11.856 | 9.82 ± 6.965 | -13.74 ± 29.664 | 10.46 ± 12.093 | 23.94 ± 11.321 |
A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| percentage of participants | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Baseline (BL): ADA Positive | 0 | 0 | 0 |
| BL: ADA Negative | 100.0 | 87.5 | 92.3 |
| BL: Missing | 0 | 12.5 | 7.7 |
| On-treatment: ADA Positive | 0 | 0 | 3.8 |
| On-treatment: Persistent Positive | 0 | 0 | 0 |
| On-treatment: Only last sample Positive | 0 | 0 | 0 |
| On-treatment: Other Positive | 0 | 0 | 3.8 |
| On-treatment: ADA Negative | 100.0 | 100.0 | 96.2 |
| On-treatment: ADA Negative, BL Positive, No Boost | 0 | 0 | 0 |
| On-treatment: Missing | 0 | 0 | 0 |
Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| pg/mL | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Baseline | 986.8 ± 363.69 | 1358.4 ± 964.47 | 1159.3 ± 601.29 |
| Day 4 | 421.4 ± 70.60 | 321.3 ± 165.91 | 58.3 ± 33.20 |
| Day 5 | 446.6 ± 108.81 | 357.8 ± 166.27 | 66.1 ± 39.07 |
| Day 8 | 522.7 ± 131.51 | 479.2 ± 319.13 | 206.8 ± 419.21 |
| Day 15 | 478.4 ± 111.44 | 280.8 ± 148.53 | 54.8 ± 61.85 |
| Day 22 | 382.4 ± 82.58 | 284.8 ± 324.16 | 35.3 ± 51.45 |
| Day 29 | 372.3 ± 79.97 | 179.0 ± 137.39 | 24.8 ± 27.24 |
| Day 33 | 291.1 ± 77.55 | 115.7 ± 84.49 | 24.3 ± 30.64 |
| Week 12 | 394.0 ± 179.78 | 115.0 ± 62.23 | 18.1 ± 13.37 |
| Week 24 | 357.9 ± 137.56 | 139.1 ± 111.63 | 23.0 ± 23.68 |
| Week 25 | 331.0 ± 116.78 | 154.5 ± 115.21 | 22.8 ± 18.48 |
| Week 36 | 340.3 ± 98.24 | 81.4 ± 36.00 | 21.1 ± 22.03 |
| Week 48 | 401.3 ± 233.76 | 79.0 ± 37.85 | 18.6 ± 12.11 |
| Week 60 | 284.6 ± 96.92 | 90.4 ± 39.30 | 36.3 ± 54.13 |
| Week 72 | 326.8 ± 151.29 | 132.0 ± 146.37 | 205.7 ± 321.58 |
| Week 84 | 534.0 ± 260.31 | 74.2 ± 13.58 | 115.6 ± 146.44 |
| Week 108 | 320.9 ± 222.10 | 84.4 ± 61.19 | 40.2 ± 42.70 |
| Week 132 | 283.5 ± 103.73 | 71.0 ± 40.02 | 40.2 ± 38.26 |
| Week 144 | — | 95.2 ± NA | — |
| Week 156 | 208.7 ± 64.52 | 48.9 ± 22.42 | 20.0 ± 0.00 |
| Week 180 | 212.5 ± 146.37 | — | — |
| Week 252 | — | 20.0 ± NA | — |
Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| percentage inhibition | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 |
|---|---|---|---|
| Day 4 | 49.689 ± 11.7394 | 73.533 ± 9.8637 | 95.334 ± 2.4477 |
| Day 5 | 46.506 ± 9.0917 | 69.700 ± 10.3411 | 94.545 ± 2.7608 |
| Day 8 | 38.411 ± 7.0320 | 62.524 ± 9.7074 | 84.797 ± 22.1958 |
| Day 15 | 40.763 ± 10.0071 | 77.090 ± 6.2939 | 96.488 ± 1.9665 |
| Day 22 | 51.836 ± 9.3488 | 81.693 ± 5.7392 | 97.927 ± 1.1259 |
| Day 29 | 52.926 ± 6.6001 | 86.894 ± 2.9590 | 98.202 ± 1.4590 |
| Day 33 | 61.796 ± 4.5760 | 91.557 ± 2.6444 | 97.042 ± 5.4443 |
| Week 12 | 58.934 ± 8.7345 | 92.025 ± 2.0548 | 98.208 ± 1.5605 |
| Week 24 | 63.199 ± 5.3419 | 89.664 ± 5.0245 | 98.009 ± 1.8677 |
| Week 25 | 62.446 ± 7.0668 | 88.689 ± 4.8868 | 97.974 ± 1.8259 |
| Week 36 | 64.103 ± 5.3774 | 92.057 ± 2.6300 | 98.470 ± 0.8410 |
| Week 48 | 58.161 ± 15.7101 | 92.237 ± 3.4952 | 98.036 ± 1.4516 |
| Week 60 | 66.280 ± 8.4684 | 90.974 ± 2.1780 | 97.177 ± 2.8783 |
| Week 72 | 65.956 ± 8.2066 | 92.536 ± 2.4445 | 79.193 ± 31.9504 |
| Week 84 | 54.990 ± 11.0397 | 92.328 ± 5.7945 | 89.744 ± 13.0990 |
| Week 108 | 70.498 ± 15.2905 | 92.412 ± 3.3662 | 95.884 ± 3.5214 |
| Week 132 | 71.129 ± 4.9576 | 92.935 ± 3.8121 | 96.713 ± 2.4278 |
| Week 144 | — | 94.732 ± NA | — |
| Week 156 | 74.712 ± 5.7764 | 94.881 ± 1.3726 | 98.183 ± 0.8086 |
| Week 180 | 75.374 ± 9.5968 | — | — |
| Week 252 | — | 96.283 ± NA | — |
Participants in the Placebo arm received placebo during the double-blind (DB) period (up to Week 24) and received RO7239361 during the open label (OL) phase. PFS in table row title indicates when study drug was changed from vial to prefilled syringe (PFS). Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.
| ng/mL | Placebo, Then RO7239361 | Panel 1 RO7239361 Whole Study | Panel 2 RO7239361 Whole Study | Panel 3 and Expansion Panel RO7239361 Whole Study |
|---|---|---|---|---|
| Day 4 | 1.178 ± 1.8833 | 5.070 ± 0.9456 | 12.606 ± 5.7623 | 14.696 ± 5.7926 |
| Day 5 | 2.119 ± 2.9826 | 5.845 ± 2.5725 | 14.856 ± 7.6131 | 17.308 ± 7.5955 |
| Day 8 | 4.924 ± 12.9975 | 7.041 ± 2.3470 | 19.906 ± 9.8664 | 21.609 ± 11.0880 |
| Day 15 | 0.613 ± 0.2102 | 14.067 ± 7.1096 | 29.229 ± 10.4929 | 45.289 ± 18.7600 |
| Day 22 | 1.326 ± 1.3410 | 11.985 ± 4.8243 | 36.811 ± 26.8560 | 52.841 ± 21.5542 |
| Day 29 | 1.593 ± 3.1007 | 15.735 ± 4.2010 | 43.236 ± 34.0300 | 67.255 ± 27.9376 |
| Day 33 | 1.157 ± 1.0036 | 18.542 ± 3.9874 | 46.279 ± 24.1457 | 77.142 ± 32.4153 |
| Week 12 | 7.082 ± 15.2289 | 28.556 ± 22.7890 | 79.555 ± 17.2126 | 88.402 ± 29.8080 |
| Week 24 (end of DB period) | 3.589 ± 7.8108 | 25.997 ± 6.4384 | 83.262 ± 64.2281 | 101.406 ± 45.4197 |
| Week 25 (Week 1 OL) | 3.186 ± 6.9734 | 31.963 ± 8.0240 | 77.926 ± 56.9987 | 102.211 ± 40.2284 |
| Week 36 (Week 12 OL) | 95.788 ± 88.1521 | 22.584 ± 8.6839 | 57.164 ± 25.8284 | 101.234 ± 42.0902 |
| Week 48 (Week 24 OL) | 90.593 ± 73.7102 | 27.461 ± 7.2306 | — | 103.657 ± 45.8802 |
| Week 60 (Week 36 OL) | 63.358 ± 37.5591 | 41.779 ± 34.2407 | 89.712 ± 38.9214 | 67.163 ± 8.4904 |
| Week 72 (Week 48 OL) | 92.086 ± 68.5222 | 26.740 ± 3.0256 | 0.550 ± NA | 102.025 ± 31.4717 |
| Week 84 (Week 60 OL) | 146.950 ± 131.3706 | 27.110 ± 3.2527 | — | 117.719 ± 41.1143 |
| Week 108 (Week 84 OL) | 122.610 ± 87.1911 | 36.014 ± 10.9338 | 66.020 ± 7.2878 | 114.806 ± 32.7432 |
| Week 132 (Week 108 OL) | 95.811 ± 48.1440 | 32.133 ± 8.2848 | 75.040 ± 14.3015 | 107.378 ± 37.8814 |
| Week 144 (Week 120 OL) | — | 25.600 ± NA | — | — |
| Week 156 (Week 132 OL) | 95.529 ± 48.0065 | 30.186 ± 7.0053 | 69.325 ± 17.7064 | 108.100 ± 35.5833 |
| Week 156 (Week 132 OL: Day 1 PFS) | 64.400 ± 0.5657 | — | — | — |
| Week 156 (Week 132 OL: Week 12 PFS) | 152.000 ± NA | — | — | 125.583 ± 44.4144 |
| Week 168 (Week 144 OL: Day 1 PFS) | 105.700 ± 54.5772 | — | 70.100 ± 25.1213 | 122.633 ± 91.2542 |
| Week 168 (Week 144 OL: Day 8 PFS) | — | — | — | 119.000 ± NA |
| Week 168 (Week 144 OL: Week 12 PFS) | — | — | 94.900 ± NA | — |
| Week 180 (Week 156 OL) | 45.933 ± 28.3161 | 25.589 ± 12.2478 | 103.300 ± 16.5463 | — |
| Week 180 (Week 156 OL: Week 12 PFS) | — | 62.600 ± NA | — | — |
| Week 192 (Week 168 OL: Day 1 PFS) | — | 18.000 ± NA | — | — |
| Week 192 (Week 168 OL: Day 45 PFS) | — | 80.400 ± NA | — | — |
| Week 252 (Week 228 OL) | 96.770 ± 61.6084 | 52.680 ± 20.8619 | 87.900 ± 38.5763 | 106.071 ± 48.6434 |
Collected over Baseline up to Week 252. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Double-Blind | 0/11 (0%) | 1/11 (9.1%) | 9/11 (81.8%) |
| Panel 1 RO7239361 Double-Blind | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Panel 2 RO7239361 Double-Blind | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Panel 3 and Expansion Panel RO7239361 Double-Blind | 0/19 (0%) | 1/19 (5.3%) | 17/19 (89.5%) |
| Panel 1 RO7239361 Open-Label | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Panel 2 RO7239361 Open-Label | 0/8 (0%) | 2/8 (25%) | 6/8 (75%) |
| Panel 3 and Expansion Panel RO7239361 Open-Label | 0/26 (0%) | 1/26 (3.8%) | 24/26 (92.3%) |
| Event | Placebo Double-Blind | Panel 1 RO7239361 Double-Blind | Panel 2 RO7239361 Double-Blind | Panel 3 and Expansion Panel RO7239361 Double-Blind | Panel 1 RO7239361 Open-Label | Panel 2 RO7239361 Open-Label | Panel 3 and Expansion Panel RO7239361 Open-Label |
|---|---|---|---|---|---|---|---|
| INFLUENZAInfections and infestations | 0/11 | 0/7 | 0/6 | 0/19 | 0/9 | 1/8 | 0/26 |
| RHABDOMYOLYSISMusculoskeletal and connective tissue disorders | 0/11 | 0/7 | 0/6 | 0/19 | 0/9 | 1/8 | 0/26 |
| CONVERSION DISORDERPsychiatric disorders | 0/11 | 0/7 | 0/6 | 0/19 | 0/9 | 1/8 | 0/26 |
| APPENDICITIS PERFORATEDInfections and infestations | 0/11 | 0/7 | 0/6 | 0/19 | 1/9 | 0/8 | 0/26 |
| SKULL FRACTUREInjury, poisoning and procedural complications | 1/11 | 0/7 | 0/6 | 0/19 | 0/9 | 0/8 | 0/26 |
| SPINAL COMPRESSION FRACTUREInjury, poisoning and procedural complications | 0/11 | 0/7 | 0/6 | 1/19 | 0/9 | 0/8 | 0/26 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 0/11 | 0/7 | 0/6 | 0/19 | 0/9 | 0/8 | 1/26 |
| Event | Placebo Double-Blind | Panel 1 RO7239361 Double-Blind | Panel 2 RO7239361 Double-Blind | Panel 3 and Expansion Panel RO7239361 Double-Blind | Panel 1 RO7239361 Open-Label | Panel 2 RO7239361 Open-Label | Panel 3 and Expansion Panel RO7239361 Open-Label |
|---|---|---|---|---|---|---|---|
| FALLInjury, poisoning and procedural complications | 0/11 | 1/7 | 0/6 | 1/19 | 7/9 | 0/8 | 6/26 |
| INJECTION SITE IRRITATIONGeneral disorders | 0/11 | 1/7 | 0/6 | 0/19 | 5/9 | 0/8 | 0/26 |
| COUGHRespiratory, thoracic and mediastinal disorders | 2/11 | 0/7 | 0/6 | 2/19 | 1/9 | 4/8 | 7/26 |
| RASHSkin and subcutaneous tissue disorders | 0/11 | 0/7 | 3/6 | 1/19 | 0/9 | 0/8 | 2/26 |
| VOMITINGGastrointestinal disorders | 1/11 | 1/7 | 0/6 | 4/19 | 4/9 | 1/8 | 8/26 |
| INJECTION SITE ERYTHEMAGeneral disorders | 0/11 | 0/7 | 0/6 | 1/19 | 4/9 | 0/8 | 8/26 |
| NASOPHARYNGITISInfections and infestations | 1/11 | 1/7 | 1/6 | 4/19 | 4/9 | 1/8 | 7/26 |
| CONTUSIONInjury, poisoning and procedural complications | 1/11 | 1/7 | 0/6 | 0/19 | 4/9 | 0/8 | 4/26 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/11 | 0/7 | 2/6 | 4/19 | 0/9 | 1/8 | 11/26 |
| HEADACHENervous system disorders | 2/11 | 2/7 | 1/6 | 7/19 | 2/9 | 0/8 | 9/26 |
Doses tested in this study were based upon achieving and maintaining moderate (\> 50% suppression), high (\> 85%), and near complete (\> 95%) suppression of serum free myostatin levels for Panels 1, 2, and 3 and Expansion Panel, respectively. Panel 3 was expanded after at least 2 weeks of dosing had been complete by at least 6 participants.
| Age, Continuous(Years) | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 | Total |
|---|---|---|---|---|---|
| Mean | 8.8 ± 1.33 | 8.0 ± 2.24 | 8.0 ± 1.79 | 8.1 ± 1.81 | 8.2 ± 1.74 |
| Sex: Female, Male(Participants) | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 11 | 7 | 6 | 19 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 | 4 |
| Not Hispanic or Latino | 9 | 7 | 5 | 13 | 34 |
| Unknown or Not Reported | 1 | 0 | 0 | 4 | 5 |
| Race (NIH/OMB)(Participants) | Placebo | Panel 1 RO7239361 | Panel 2 RO7239361 | Panel 3 and Expansion Panel RO7239361 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 2 | 0 | 2 | 5 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 9 | 6 | 3 | 13 | 31 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Feb 2018, 26 months.
Results were first posted in May 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Taldefgrobep alfa